Related references
Note: Only part of the references are listed.An analysis of reference laboratory testing in a large urban academic medical center: The impact of new molecular diagnostic technologies
Linda Ardisson et al.
LABMEDICINE (2007)
Survey of treatment recommendations for anaplastic oligodendroglioma
Lauren E. Abrey et al.
NEURO-ONCOLOGY (2007)
Temozolomide for low-grade gliomas - Predictive impact of 1p/19q loss on response and outcome
G. Kaloshi et al.
NEUROLOGY (2007)
Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme
Ramon Martinez et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Opinion - Shaping the future of biomarker research in breast cancer to ensure clinical relevance
M. Carolina Hinestrosa et al.
NATURE REVIEWS CANCER (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma:: New approaches to brain tumor therapy CNS consortium trial
Jon Weingart et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Downregulation of RUNX3 and TES by hypermethylation in glioblastoma
W. Mueller et al.
ONCOGENE (2007)
Single nucleotide polymorphism array analysis of cancer
Amit Dutt et al.
CURRENT OPINION IN ONCOLOGY (2007)
Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity
Cory Allen et al.
CANCER RESEARCH (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification -: A feasibility study
Raymond R. Tubbs et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2006)
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
Jeffrey C. Lee et al.
PLOS MEDICINE (2006)
MGMT methylation:: A marker of response to temozolomide in low-grade gliomas
Sibille Everhard et al.
ANNALS OF NEUROLOGY (2006)
New approaches to molecular cancer therapeutics
Ian Collins et al.
NATURE CHEMICAL BIOLOGY (2006)
The application of microarray technology to neuropathology: Cutting edge tool with clinical diagnostics potential or too much information?
Andrew McShea et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Robert B. Jenkins et al.
CANCER RESEARCH (2006)
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
Jill A. Maxwell et al.
MOLECULAR CANCER THERAPEUTICS (2006)
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Mathilde C. M. Kouwenhoven et al.
EUROPEAN JOURNAL OF CANCER (2006)
Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss
Constance A. Griffin et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling
Bjoern Tews et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
O6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas:: Results from the CCG-945 cohort
Ian F. Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
Pasi A. Jaenne et al.
CLINICAL CANCER RESEARCH (2006)
Reclassification of oligoastrocytomas by loss of heterozygosity studies
Marica Eoli et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
C. Walker et al.
NEUROLOGY (2006)
Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas
C. Kersting et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Progressive low-grade oligodendrogliomas -: Response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression
N Levin et al.
CANCER (2006)
Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme - Prognostic significance and relationship to other prognostic factors
LJ Layfield et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2006)
Changing paradigms - An update on the multidisciplinary management of malignant glioma
Roger Stupp et al.
ONCOLOGIST (2006)
BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH)
B Ylstra et al.
NUCLEIC ACIDS RESEARCH (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Biomarkers in cancer staging, prognosis and treatment selection
JA Ludwig et al.
NATURE REVIEWS CANCER (2005)
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
AB Lassman et al.
CLINICAL CANCER RESEARCH (2005)
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
JA Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors
JM McDonald et al.
CANCER (2005)
Oligodendroglioma: Impact of molecular biology on its definition, diagnosis and management
K Ueki
NEUROPATHOLOGY (2005)
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas
M Brell et al.
CLINICAL CANCER RESEARCH (2005)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods?
AP Dei Tos et al.
EUROPEAN JOURNAL OF CANCER (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Comparative genomic hybridization
D Pinkel et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS (2005)
Molecular markers for diagnosis and prognosis
M Partridge et al.
CANCER AND METASTASIS REVIEWS (2005)
Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma
C Kersting et al.
LABORATORY INVESTIGATION (2004)
Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms
AR Judkins et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
MGMT: Its role in cancer aetiology and cancer therapeutics
SL Gerson
NATURE REVIEWS CANCER (2004)
Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival
J Felsberg et al.
BRAIN PATHOLOGY (2004)
Intragenic ERBB2 kinase mutations in tumours
P Stephens et al.
NATURE (2004)
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions
K Hoang-Xuan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Correlations between molecular profile and radiologic pattern in oligodendroglial tumors
F Laigle-Donadey et al.
NEUROLOGY (2004)
Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas
S Nakasu et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prognostic and predictive markers in cancer
BA Conley et al.
DISEASE MARKERS (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology
G Reifenberger et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
Phosphorylation state-specific antibodies applications in investigative and diagnostic pathology
JW Mandell
AMERICAN JOURNAL OF PATHOLOGY (2003)
Frequent promoter hypermethylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene in testicular cancer
B Smith-Sorensen et al.
ONCOGENE (2002)
The molecular and genetic basis of neurological tumours
YA Zhu et al.
NATURE REVIEWS CANCER (2002)
Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p
A Mukasa et al.
ONCOGENE (2002)
Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression
K Hoang-Xuan et al.
NEUROLOGY (2001)
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
MS Neshat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay
JM Nigro et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
A role for fluorescence in situ hybridization detection of chromosome 22q dosage in distinguishing atypical teratoid/rhabdoid tumors from medulloblastoma/central primitive neuroectodermal tumors
LA Bruch et al.
HUMAN PATHOLOGY (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
GS Bauman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
JS Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
